April 29, 2025

Richard Pazdur, MD, Honored With 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine

During the 2025 American Association for Cancer Research (AACR) Annual Meeting, Richard Pazdur, MD, accepted an award and gave remarks during the meeting’s Opening Ceremony.

The ASCO Post

April 29, 2025

AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer

The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation,...

The ASCO Post

April 29, 2025

AACR 2025: Novel Targeted Therapy Under Study in Selected Patients With Advanced Solid Tumors

According to the results of a phase I trial, the first-in-class covalent Werner helicase inhibitor (RO7589831) demonstrated early signals of efficacy as well as general tolerability in patients with a...

The ASCO Post

April 29, 2025

AACR 2025: Pretrained AI Models Could Help Accurately Diagnose Nonmelanoma Skin Cancers in Resource-Limited Settings

Researchers explored whether artificial intelligence (AI) models pretrained on vast data sets may outperform standard baseline models in identifying nonmelanoma skin cancers, according to findings pre...

The ASCO Post

April 29, 2025

AACR 2025: AI-Driven Model For Identifying Cancer Cachexia

Use of a multimodal deep learning–based model led to more accurate and earlier identifications of cancer cachexia than standard clinical and radiological observations, according to findings presented ...

The ASCO Post

April 29, 2025

Patient-Reported Outcomes With Mirvetuximab Soravtansine vs Chemotherapy in FRα-Positive, Platinum-Resistant Ovarian Cancer

An analysis of the phase III MIRASOL trial evaluated quality-of-life outcomes in patients receiving mirvetuximab soravtansine vs chemotherapy for FRα-positive, platinum-resistant ovarian cancer.

The ASCO Post

April 29, 2025

Combination Therapy for Newly Diagnosed, BRCA-Nonmutated, Advanced Epithelial Ovarian Cancer

The outcomes from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial in advanced BRCA-nonmutated ovarian cancer indicate a statistically significant and clinically meaningful benefit for the PD-1 inh...

The ASCO Post

April 28, 2025

AACR 2025: Zoldonrasib May Elicit Objective Responses in Patients With KRAS G12D–Mutated NSCLC

Researchers have examined the clinical benefit of the oral KRAS G12D inhibitor zoldonrasib in patients with previously treated non–small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D muta...

The ASCO Post

April 28, 2025

AACR 2025: Nonoperative Management of Mismatch Repair–Deficient Tumors

PD-1 blockade with the PD-1 inhibitor dostarlimab-gxly induced complete tumor clearance and resolved the need for surgery in patients with locally advanced, mismatch repair–deficient cancers, accordin...

The ASCO Post